Latest Ratios: P/E Ratio -4.9x · EV/EBITDA N/A · ROE -110.0%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $412M | $315M | $202M | $305M | $132M | $780M | — | — |
| Enterprise Value | $405M | $308M | $152M | $200M | $-12517621 | $600M | — | — |
| P/E Ratio → | -4.91 | — | — | — | — | — | — | — |
| P/S Ratio | 5.33 | 4.08 | 3.10 | 4.89 | 2.78 | 19.28 | — | — |
| P/B Ratio | 8.24 | 6.69 | 2.09 | 2.01 | 0.66 | 2.83 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.99 | 2.33 | 3.21 | -0.26 | 14.83 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.9% | 61.9% | 67.4% | 68.8% | 65.7% | 62.4% | 62.3% | 70.3% |
| Operating Margin | -91.8% | -91.8% | -102.1% | -120.0% | -184.7% | -176.7% | -131.6% | -127.3% |
| Net Profit Margin | -102.2% | -102.2% | -95.9% | -126.6% | -183.9% | -182.1% | -138.5% | -133.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -110.0% | -110.0% | -50.4% | -44.9% | -36.8% | -39.2% | -64.1% | -151.8% |
| ROA | -49.6% | -49.6% | -34.6% | -35.1% | -31.0% | -32.6% | -42.8% | -65.4% |
| ROIC | -123.5% | -123.5% | -107.3% | -109.7% | -87.2% | -83.4% | -122.5% | -191.5% |
| ROCE | -58.8% | -58.8% | -44.5% | -38.6% | -34.5% | -35.6% | -52.3% | -99.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.34 | 1.34 | 0.31 | 0.12 | 0.08 | 0.05 | 0.07 | 0.38 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.15 | -0.52 | -0.69 | -0.72 | -0.65 | -0.67 | -0.43 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -15.57 | -15.57 | -31.03 | -132.49 | -136.07 | -110.71 | -48.08 | -33.46 |
Net cash position: cash ($70M) exceeds total debt ($63M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.96 | 1.96 | 3.71 | 4.16 | 7.32 | 9.89 | 5.08 | 1.75 |
| Quick Ratio | 1.84 | 1.84 | 3.49 | 3.97 | 7.13 | 9.69 | 4.92 | 1.57 |
| Cash Ratio | 1.39 | 1.39 | 2.99 | 3.46 | 6.66 | 9.28 | 4.51 | 0.96 |
| Asset Turnover | — | 0.47 | 0.42 | 0.30 | 0.20 | 0.13 | 0.21 | 0.49 |
| Inventory Turnover | 4.64 | 4.64 | 3.62 | 3.00 | 3.16 | 2.66 | 3.16 | 2.09 |
| Days Sales Outstanding | — | 87.51 | 48.67 | 88.98 | 61.80 | 63.97 | 100.94 | 139.67 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $68M | $66M | $65M | $64M | $55M | $48M | $64M |
Insufficient liquidity for operations
Based on current market data, SOPH trades at a price-to-sales multiple of 5.33, a valuation that appears aggressive given the company's persistent negative net margins and the significant capital requirements necessary to sustain its global platform expansion in the competitive healthcare informatics sector.
The current P/S multiple suggests that investors are pricing in a high-growth trajectory that assumes a rapid transition to profitability, which remains unproven by current financial results. Compared to peers like Veracyte, which demonstrates positive margins, SOPH's valuation appears disconnected from its current inability to generate positive earnings or free cash flow.
As reported in recent financial statements, SOPH's ROIC has remained consistently negative, hovering around -31.4% in 2026Q1, which indicates that the company is currently destroying shareholder value rather than compounding it through its heavy investments in platform development and global market penetration.
The persistent negative return on invested capital suggests that the firm's cost of growth significantly outweighs the marginal returns generated by its diagnostic platform. This trend warrants close monitoring, as it implies that the current business model requires fundamental structural changes to achieve a positive return on capital employed.
According to quarterly filings, SOPH's cash conversion cycle has shown significant volatility, reaching 15 days in 2026Q1, which reflects the inherent challenges in managing a decentralized platform model where revenue recognition is tied to variable diagnostic analysis events across diverse global hospital networks.
The fluctuation in the cash conversion cycle suggests that the company struggles with consistent collection timing, potentially due to the complexity of its international client base. Investors should monitor whether this volatility stabilizes as the company scales, as inefficient working capital management further strains the firm's limited liquidity.
Based on the provided balance sheet data, SOPH's debt-to-equity ratio has climbed to 1.37 as of 2026Q1, signaling an increasing reliance on external financing to bridge the gap between its high operating expenses and its current revenue generation capabilities in a tightening credit environment.
The rapid increase in leverage, combined with negative interest coverage ratios, suggests that the company's debt service capacity is becoming increasingly precarious. This trend indicates that the firm may face significant refinancing risks if it cannot achieve self-sustaining cash flows in the near term.
Market participants frequently misapply the price-to-sales ratio to SOPH, which obscures the company's underlying cash burn and the high cost of maintaining its cloud-based infrastructure, ultimately failing to account for the significant capital intensity required to support its decentralized genomic data platform.
Because SOPH operates as a high-burn informatics platform rather than a traditional software-as-a-service firm, revenue multiples ignore the substantial variable cloud costs that compress gross margins. Analysts should instead focus on the ratio of cash burn to platform analysis volume to better assess the company's true path to operational sustainability.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SOPH stock.
SOPHiA GENETICS S.A.'s current P/E ratio is -4.9x. This places it at the 50th percentile of its historical range.
SOPHiA GENETICS S.A.'s return on equity (ROE) is -110.0%. The historical average is -71.0%.
Based on historical data, SOPHiA GENETICS S.A. is trading at a P/E of -4.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
SOPHiA GENETICS S.A. has 61.9% gross margin and -91.8% operating margin.